Tolerogenic Vaccination with MOG/VitD Overcomes Aggravating Effect of C-albicans in Experimental Encephalomyelitis

Author(s)

Fraga-Silva, Thais F. C. ; Mimura, Luiza A. N. ; Zorzella-Pezavento, Sofia F. G. ; Ishikawa, Larissa L. W. ; Franca, Thais G. D. ; Thome, Rodolfo ; Verinaud, Liana ; Arruda, Maria S. P. ; Sartori, Alexandrina

• Document type: Journal article
• Source: CNS Neuroscience & Therapeutics; v. 22, n. 10, p. 807-816, OCT 2016.
• Web of Science Citations: 2

Abstract

AimsMultiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous system (CNS). We described that Candida albicans (Ca) aggravates experimental autoimmune encephalomyelitis (EAE) that is a model to study MS. We also observed that vaccination with a myelin peptide (MOG) in the presence of vitamin D (VitD) protected mice against EAE. In this work, we investigated whether Ca infection interferes with the efficacy of this vaccine. MethodsEAE was induced in C57BL/6 female mice previously vaccinated with MOG+VitD and then infected 3 days before encephalomyelitis induction. ResultsVaccination was able to control EAE development in infected mice. These animals gained weight, and only a few progressed to very low clinical scores. Protection was confirmed by a lower inflammatory infiltration in the CNS and was also associated with a reduced production of encephalitogenic cytokines by spleen and CNS cell cultures. The elevated percentage of CD25(+)FoxP3(+) cells suggests that regulatory T cells are involved in the protection. Adoptive transfer of splenocytes from mice vaccinated with MOG+VitD supports the view that protection is mediated by immunoregulatory cells. ConclusionTogether, these experiments provide evidence demonstrating that EAE can be prevented by the inverse vaccination with MOG+VitD even in the presence of a disease-aggravating infectious agent. (AU)

• FAPESP's process: 12/12540-7 - Effect of Candida albicans infection on experimental autoimmune encephalitis
• Grantee: Maria Sueli Parreira de Arruda
• Support Opportunities: Regular Research Grants